Andrew Mathis assists the firm in biotechnology patent drafting, prosecution, and counseling. He works with clients in many technology areas, including cell therapy, protein biologics, gene editing, nanoparticles, antisense oligonucleotides, DNA sequencing, and bioinformatics. He has extensive knowledge in the areas of CRISPR interference, continuous culture, Illumina DNA sequencing, systems biology, molecular biology, and proteomics mass spectrometry. Andrew also has significant experience in computational biology and bioinformatics.
An article authored by Andrew Mathis titled “Making Patent Prosecution More Collaborative” was published in the Massachusetts Bar Association’s November/December 2024 issue of Section Review. In this ...
